NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England
Industry Has Mixed Response To “Largest And Most Comprehensive Review”
Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.
You may also be interested in...
Pharma Firms Keep A Close Eye On NICE's New HTA Approach In UK
Companies are keen to know how the disease severity modifier and a more flexible approach to uncertainty will be applied to health technology appraisals for drugs in practice. They also want reassurance that there will be consistency in deliberations by NICE’s various committees and advisory groups.
UK Should Look To France To Speed Up Access To Innovative Medicines
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.
US Industry Hauls Post-Brexit UK Over The Coals
PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.